Halozyme Therapeutics (HALO) Change in Accured Expenses (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Change in Accured Expenses data on file, last reported at -$24.9 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$24.9 million, down 370.33% year-over-year; the trailing twelve-month figure through Mar 2026 was -$27.9 million (down 174.43% YoY), and the FY2025 annual result was $6.2 million, down 86.78% from the prior year.
• Change in Accured Expenses fell to -$24.9 million in Q1 2026 per HALO's latest filing, from $33.8 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $50.2 million in Q4 2024 and troughed at -$29.7 million in Q2 2025.
• A 5-year average of $2.4 million and a median of -$2.0 million in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses plunged 3007.67% in 2023, then surged 629.44% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $326000.0 in 2022, then sank by 3007.67% to -$9.5 million in 2023, then surged by 629.44% to $50.2 million in 2024, then sank by 32.55% to $33.8 million in 2025, then slumped by 173.63% to -$24.9 million in 2026.
• Business Quant data shows HALO's Change in Accured Expenses at -$24.9 million in Q1 2026, $33.8 million in Q4 2025, and -$7.2 million in Q3 2025.